非小细胞肺癌患者肿瘤病灶[18F]F-AraG PET显像的药代动力学分析与简化摄取指标
研究纳入10例早期和3例晚期非小细胞肺癌患者,行动态PET扫描,比较单组织可逆、双组织不可逆和双组织可逆血浆输入模型,发现2T3k模型拟合最佳;20–70分钟任意时间间隔的SUV、TBR和TPR均与2T3k衍生的Ki强正相关,其中60–70分钟TBR相关性最强。
要点
- 肿瘤病灶[18F]F-AraG摄取最佳药代动力学模型为双组织不可逆(2T3k)模型。
- 20–70分钟任意时间间隔的SUV、TBR和TPR均与2T3k衍生Ki强正相关。
- 60–70分钟TBR与2T3k衍生Ki的相关性(r=0.87)强于SUVBW(r=0.80)。
核心结论
- 非小细胞肺癌患者肿瘤病灶[18F]F-AraG摄取以2T3k模型为特征,TBR和TPR在简化定量方面最具潜力。
研究设计与样本
- 纳入10例早期和3例晚期非小细胞肺癌患者,行动态PET扫描至少60分钟。
- 静脉和/或动脉血采样最多7个时间点,分析肿瘤病灶时间活度曲线和代谢物校正输入函数。
主要发现
- 全血和血浆放射性浓度显示[18F]F-AraG快速清除。
- 注射后70分钟时,血液中总放射性平均79%(SD=9.8%)为完整[18F]F-AraG。
- 时间活度曲线最佳拟合模型为2T3k模型。
- 注射后20至70分钟任意时间间隔的SUV(按体重、瘦体重或体表面积校正)、TBR和TPR均与2T3k衍生Ki呈强正相关。
- 注射后60–70分钟TBR与2T3k衍生Ki的相关性(r(df=20)=0.87,p<0.01)强于SUVBW(r(df=20)=0.80,p<0.01)。
关键数值与推荐
- 注射后70分钟时,血液中完整[18F]F-AraG占总放射性平均79%(SD=9.8%)。
- 注射后60–70分钟TBR与2T3k衍生Ki的相关系数r(df=20)=0.87,p<0.01。
- 注射后60–70分钟SUVBW与2T3k衍生Ki的相关系数r(df=20)=0.80,p<0.01。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The novel positron emission tomography (PET) imaging tracer, [18F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [18F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter. METHODS: Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input functions were analysed using single-tissue reversible (1T2k), two-tissue irreversible (2T3k) and two-tissue reversible (2T4k) plasma input models. Simplified uptake measures, such as standardised uptake value (SUV) and tumour-to-blood (TBR) or tumour-to-plasma ratio (TPR), were evaluated for different time intervals. RESULTS: Whole-blood and plasma radioactivity concentrations showed rapid clearance of [18F]F-AraG. Metabolite analysis revealed a low rate of metabolism, at 70 min p.i., on average, 79% (SD = 9.8%) of the total radioactivity found in blood corresponded to intact [18F]F-AraG. The time activity curves were best fitted by the 2T3k model. Strong positive correlations were found for SUV (body weight (BW), lean body mass (LBM) or body surface area (BSA) corrected), TBR and TPR for any time interval between 20 and 70 min p.i. against the 2T3k-derived Ki. The correlation of TBR at 60-70 min p.i. with 2T3K-derived Ki (r (df = 20) = 0.87, p < 0.01), was stronger than for SUVBW (r (df = 20) = 0.80, p < 0.01). CONCLUSION: Tumour lesion [18F]F-AraG uptake in patients with NSCLC is characterised by a 2T3k model. TBR and TPR show most potential for simplified quantification of tumour lesion [18F]F-AraG uptake in patients with NSCLC.
引用
- Wijngaarden JE, Slebe M, Pouw JEE, et al. Pharmacokinetic analysis and simplified uptake measures for tumour lesion [18F]F-AraG PET imaging in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2024. PMID: 39377810. doi:10.1007/s00259-024-06931-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。